Technology ID
TAB-3535
Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL)
E-Numbers
E-069-2011-0
Lead Inventor
Auld, Douglas (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Shen, Min (National Human Genome Research Institute (NIH/NHGRI))
Austin, Christopher (National Human Genome Research Institute (NIH/NHGRI))
Wiestner, Adrian (NHLBI)
Applications
Therapeutics
Therapeutic Areas
Oncology
Lead IC
NCATS
ICs
NHLBI
This technology includes the use of auranofin for the treatment of Chronic Lymphocytic Leukemia (CLL). Auranofin is currently approved for the treatment of rheumatoid arthritis and has been shown to display anti-cancer activity. CLL is a blood and bone marrow disease that usually progresses over a lengthy period of time and normally occurs in middle-age adults. The current therapeutic options for CLL patients are limited, and there are few therapies under development. Using an in vitro assay against primary lymphocytes from patients with CLL, auranofin was identified as a drug repurposing candidate for the treatment of CLL.
Commercial Applications
Further clinical work with auranofin could establish this drug for the treatment of chronic lympocytic leukemia (CLL).
Competitive Advantages
The use of auranofin could be the first oral therapy for treatment of CLL.
Licensing Contact: